首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   142636篇
  免费   10258篇
  国内免费   3718篇
耳鼻咽喉   988篇
儿科学   2918篇
妇产科学   1882篇
基础医学   8732篇
口腔科学   2885篇
临床医学   18447篇
内科学   23995篇
皮肤病学   2330篇
神经病学   6715篇
特种医学   4918篇
外国民族医学   39篇
外科学   14660篇
综合类   20347篇
现状与发展   23篇
一般理论   2篇
预防医学   5623篇
眼科学   2034篇
药学   11240篇
  79篇
中国医学   11260篇
肿瘤学   17495篇
  2024年   196篇
  2023年   2361篇
  2022年   3609篇
  2021年   6173篇
  2020年   5705篇
  2019年   5277篇
  2018年   5042篇
  2017年   5341篇
  2016年   5590篇
  2015年   5524篇
  2014年   10261篇
  2013年   12493篇
  2012年   8221篇
  2011年   8854篇
  2010年   7345篇
  2009年   6854篇
  2008年   6767篇
  2007年   7127篇
  2006年   6392篇
  2005年   5595篇
  2004年   4559篇
  2003年   4081篇
  2002年   3352篇
  2001年   2908篇
  2000年   2462篇
  1999年   1958篇
  1998年   1590篇
  1997年   1395篇
  1996年   1182篇
  1995年   1063篇
  1994年   864篇
  1993年   688篇
  1992年   610篇
  1991年   559篇
  1990年   477篇
  1989年   415篇
  1988年   433篇
  1987年   362篇
  1986年   285篇
  1985年   368篇
  1984年   376篇
  1983年   250篇
  1982年   264篇
  1981年   253篇
  1980年   228篇
  1979年   197篇
  1978年   123篇
  1977年   113篇
  1976年   127篇
  1975年   103篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder.  相似文献   
22.
23.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria.  相似文献   
24.
25.
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients.  相似文献   
26.
27.
28.
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号